NCT03442075

Brief Summary

Define the best analgesic method between peri prostatic blockage, analgesic suppository, oral analgesic and topic anesthetic gel, during trans rectal prostate biopsy

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
70

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started May 2017

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 1, 2017

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 31, 2017

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 31, 2017

Completed
6 months until next milestone

First Submitted

Initial submission to the registry

February 10, 2018

Completed
12 days until next milestone

First Posted

Study publicly available on registry

February 22, 2018

Completed
Last Updated

March 27, 2018

Status Verified

March 1, 2018

Enrollment Period

3 months

First QC Date

February 10, 2018

Last Update Submit

March 25, 2018

Conditions

Keywords

Cancer of ProstateAnalgesic method

Outcome Measures

Primary Outcomes (1)

  • Ultrasound Transducer

    Evaluation of the discomfort or pain in the introduction of the trans rectal ultrasound transducer determined at the end of the procedure with Visual Analog Scale for Pain, which is a psychometric measuring instrument designed to assess the pain intensity experienced by each patient individually. Was employ for first time in 1921 and referred as a "graphical rating method", which has the characteristic of being able to achieve a rapid classification (statistically measurable and reproducible) of the severity of pain experience. The analogous visual scale used for this study measures from 0-10 the intensity of the pain with a series of "faces" that show the intensity in the pain experimentation with categories like "No pain" approximately 0-1, mild, annoying in number 2, nagging in number 4, distressing in number 6, intense in number 8 and worst possible in number 10.

    Interview 15 to 30 minutes at the end of the procedure

Secondary Outcomes (1)

  • Biopsy

    Interview 15 to 30 minutes at the end of the procedure

Other Outcomes (1)

  • General procedure

    Interview 15 to 30 minutes at the end of the procedure

Study Arms (5)

Group 1

Group 1 an analgesic suppository was applied

Group 2

Group 2 was administered analgesic orally

Group 3

Group 3 was given trans rectal gel

Group 4

Group was performed peri prostatic infiltration.

Group 5

Group was performed by placebo oral

Eligibility Criteria

Age18 Years - 75 Years
Sexmale(Gender-based eligibility)
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

The patients from the consultation were taken from the first time they were derived from the peripheral clinics or from the ones derived from our same medicine, with suspicion of prostate cancer and that the criteria for carrying out the trans rectal prostate biopsy were met.

You may qualify if:

  • Male patients older than 18 years with indication for trans rectal prostate biopsy

You may not qualify if:

  • Bad intestinal preparation.
  • Painful anorectal pathologies.
  • Clotting disorders without previous assessment by hematology.
  • Acute prostatitis

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Edgar Beltran-Suarez

Mexico City, Aztcapotzalco, 07300, Mexico

Location

Related Publications (6)

  • Attard G, Parker C, Eeles RA, Schroder F, Tomlins SA, Tannock I, Drake CG, de Bono JS. Prostate cancer. Lancet. 2016 Jan 2;387(10013):70-82. doi: 10.1016/S0140-6736(14)61947-4. Epub 2015 Jun 11.

    PMID: 26074382BACKGROUND
  • Lowrance WT, Roth BJ, Kirkby E, Murad MH, Cookson MS. Castration-Resistant Prostate Cancer: AUA Guideline Amendment 2015. J Urol. 2016 May;195(5):1444-1452. doi: 10.1016/j.juro.2015.10.086. Epub 2015 Oct 20.

    PMID: 26498056BACKGROUND
  • Loeb S, Vellekoop A, Ahmed HU, Catto J, Emberton M, Nam R, Rosario DJ, Scattoni V, Lotan Y. Systematic review of complications of prostate biopsy. Eur Urol. 2013 Dec;64(6):876-92. doi: 10.1016/j.eururo.2013.05.049. Epub 2013 Jun 4.

    PMID: 23787356BACKGROUND
  • Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Schmid HP, van der Kwast T, Wiegel T, Zattoni F, Heidenreich A. [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer]. Actas Urol Esp. 2011 Nov-Dec;35(10):565-79. doi: 10.1016/j.acuro.2011.03.011. Epub 2011 Jul 14. Spanish.

    PMID: 21757258BACKGROUND
  • Herranz Amo F, Diez Cordero JM, Cabello Benavente R. [Evolution of the transrectal ultrasound guided prostatic biopsy technique]. Arch Esp Urol. 2006 May;59(4):385-96. Spanish.

    PMID: 16800136BACKGROUND
  • Sahin A, Ceylan C, Gazel E, Odabas O. Three different anesthesia techniques for a comfortable prostate biopsy. Urol Ann. 2015 Jul-Sep;7(3):339-44. doi: 10.4103/0974-7796.152014.

    PMID: 26229322BACKGROUND

Related Links

MeSH Terms

Conditions

Prostatic Neoplasms

Condition Hierarchy (Ancestors)

Genital Neoplasms, MaleUrogenital NeoplasmsNeoplasms by SiteNeoplasmsGenital Diseases, MaleGenital DiseasesUrogenital DiseasesProstatic DiseasesMale Urogenital Diseases

Study Officials

  • EDGAR BELTRAN-SUAREZ, MD

    HOSPITAL OF SPECIALTIES OF THE NATIONAL MEDICAL

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER GOV
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Dr Edgar Beltran-Suarez

Study Record Dates

First Submitted

February 10, 2018

First Posted

February 22, 2018

Study Start

May 1, 2017

Primary Completion

July 31, 2017

Study Completion

July 31, 2017

Last Updated

March 27, 2018

Record last verified: 2018-03

Data Sharing

IPD Sharing
Will not share

Locations